bioRxivImmunology
Opsonization by non-neutralizing antibodies can confer protection to SARS-CoV-2 despite Spike-dependent modulation of phagocytosis
W. Bahnan, S. Wrighton, M. Sundwall, A. Bläckberg, O. Larsson, U. Höglund, H. Khakzad, M. Godzwon, M. Walle, E. Elder, L. Happonen, O. Andre, J. Kumra Ahnlide, T. Hellmark, V. Wendel-Hansen, R. P. Wallin, J. Malmström, L. Malmström, M. Ohlin, M. Rasmussen, P. Nordenfelt
Abstract
Spike-specific antibodies are central to effective COVID19 immunity. Research efforts have focused on antibodies that neutralize the ACE2-Spike interaction but not on non-neutralizing antibodies. Antibody-dependent phagocytosis is an immune mechanism enhanced by opsonization, where typically, more bound antibodies trigger a stronger phagocyte response. Here, we show that Spike-specific antibodies, dependent on concentration, can either enhance or reduce Spike-bead phagocytosis by monocytes independently of the antibody neutralization potential. Surprisingly, we find that both convalescent patient plasma and patient-derived monoclonal antibodies lead to maximum opsonization already at low levels of bound antibodies and is reduced as antibody binding to Spike protein increases. Moreover, we show that this Spike-dependent modulation of opsonization seems to affect the outcome in an experimental SARS-CoV-2 infection model. These results suggest that the levels of anti-Spike antibodies could influence monocyte-mediated immune functions and propose that non-neutralizing antibodies could confer protection to SARS-CoV-2 infection by mediating phago-cytosis.
- organism: human
- assay: proteomics
- research focus: host-pathogen & immune response
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Longitudinal characterisation of phagocytic and neutralisation functions of anti-Spike antibodies in plasma of patients after SARS-CoV-2 infection.
A. Adhikari, A. Abayasingam, … N. Tedla·bioRxiv·Dec 21, 2021
- Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions and monocytes for optimal therapeutic protection
E. S. Winkler, P. Gilchuk, … M. Diamond·bioRxiv·Dec 28, 2020
- The functions of SARS-CoV-2 neutralizing and infection-enhancing antibodies in vitro and in mice and nonhuman primates
D. Li, R. J. Edwards, … Petzol·bioRxiv·Dec 31, 2020
- SARS-CoV-2 ORF8 limits expression levels of Spike antigen.
- Characteristics and functions of infection-enhancing antibodies to the N-terminal domain of SARS-CoV-2
R. I. Connor, M. I. Sakharkar, … P. F. Wright·bioRxiv·Sep 19, 2023
- Neutralizing and protective human monoclonal antibodies recognizing the N-terminaldomain of the SARS-CoV-2 spike protein
N. Suryadevara, S. Shrihari, … J. E. Crowe·bioRxiv·Jan 19, 2021